(ser LIP oh nase AL fa)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Injection [preservative free]:
Brineura: 150 mg/5 mL (15 mL)
Brand Names: U.S.
- Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase
Use: Labeled Indications
Neuronal ceroid lipofuscinosis type 2: Indicated to delay the loss of ambulation in symptomatic pediatric patients ≥3 years with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
Acute intraventricular access device-related complications (eg, leakage, device failure, device-related infection), ventriculoperitoneal shunts
There are no known significant interactions.